Management of opioid use disorders: a national clinical practice guideline
- PMID: 29507156
- PMCID: PMC5837873
- DOI: 10.1503/cmaj.170958
Management of opioid use disorders: a national clinical practice guideline
Conflict of interest statement
Competing interests: Julie Bruneau, Benedikt Fischer, T. Cameron Wild, and Evan Wood report grants from the Canadian Institutes of Health Research (CIHR) during the conduct of the study. Peter Selby reports grants from CIHR to the Centre for Addiction and Mental Health during the conduct of the study. Peter Selby conducted an expert review for the Canadian Agency for Drugs and Technologies in Health on a rapid analysis for a formulation of buprenorphine in the last 12 months. Marie-Ève Goyer reports payments from Indivior, Gilead Sciences, ViiV Healthcare and Merck, outside of the submitted work. Julie Bruneau reports monetary compensation as advisor from Gilead and Merck, outside of the submitted work. No other competing interests were declared.
Figures
Comment in
-
Narrowing the treatment gap in managing opioid use disorder.CMAJ. 2018 Mar 5;190(9):E236-E237. doi: 10.1503/cmaj.180209. CMAJ. 2018. PMID: 29507154 Free PMC article. No abstract available.
-
Guideline: In adults with opioid use disorders, a stepped treatment approach is recommended.Ann Intern Med. 2018 Jun 19;168(12):JC62. doi: 10.7326/ACPJC-2018-168-12-062. Ann Intern Med. 2018. PMID: 29913487 No abstract available.
-
Extended-release naltrexone overlooked in opioid use disorders guideline.CMAJ. 2018 Jul 16;190(28):E862. doi: 10.1503/cmaj.69411. CMAJ. 2018. PMID: 30012803 Free PMC article. No abstract available.
-
Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market.CMAJ. 2020 Jan 20;192(3):E73. doi: 10.1503/cmaj.74018. CMAJ. 2020. PMID: 31959660 Free PMC article. No abstract available.
Similar articles
-
Management of chronic pain and opioid dependence with buprenorphine/naloxone.Psychiatry Clin Neurosci. 2018 Jun;72(6):454. doi: 10.1111/pcn.12652. Epub 2018 Apr 10. Psychiatry Clin Neurosci. 2018. PMID: 29573109 No abstract available.
-
American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.J Addict Med. 2015 Sep-Oct;9(5):358-67. doi: 10.1097/ADM.0000000000000166. J Addict Med. 2015. PMID: 26406300 Free PMC article.
-
Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.Adolesc Med State Art Rev. 2014 Aug;25(2):251-65. Adolesc Med State Art Rev. 2014. PMID: 27132312 Review. No abstract available.
-
Use of Opioid Agonist Therapy for Medicare Patients in 2013.JAMA Psychiatry. 2016 Sep 1;73(9):990-2. doi: 10.1001/jamapsychiatry.2016.1390. JAMA Psychiatry. 2016. PMID: 27438334 Free PMC article. No abstract available.
-
Prevention of Opioid Overdose.N Engl J Med. 2019 Jun 6;380(23):2246-2255. doi: 10.1056/NEJMra1807054. N Engl J Med. 2019. PMID: 31167053 Review. No abstract available.
Cited by
-
Management of opioid use disorder: 2024 update to the national clinical practice guideline.CMAJ. 2024 Nov 11;196(38):E1280-E1290. doi: 10.1503/cmaj.241173. CMAJ. 2024. PMID: 39532476 Free PMC article.
-
Expanding access to addictions care: Implementation of a 24-hour healthcare provider support line in British Columbia, Canada.Addict Sci Clin Pract. 2024 Oct 31;19(1):76. doi: 10.1186/s13722-024-00508-z. Addict Sci Clin Pract. 2024. PMID: 39482775 Free PMC article.
-
The association between benzodiazepine co-prescription, opioid agonist treatment and mortality: a systematic review.BMC Psychiatry. 2024 Oct 28;24(1):741. doi: 10.1186/s12888-024-06191-3. BMC Psychiatry. 2024. PMID: 39468492 Free PMC article.
-
Enhancing staff confidence to initiate buprenorphine-naloxone for opioid use disorder in an Ontario ED.CJEM. 2024 Oct 24. doi: 10.1007/s43678-024-00803-3. Online ahead of print. CJEM. 2024. PMID: 39446244 No abstract available.
-
Facilitators of and barriers to buprenorphine initiation in the emergency department: a scoping review.Lancet Reg Health Am. 2024 Sep 28;38:100899. doi: 10.1016/j.lana.2024.100899. eCollection 2024 Oct. Lancet Reg Health Am. 2024. PMID: 39381082 Free PMC article. Review.
References
-
- Canadian Institute for Health Information, Canadian Centre on Substance Abuse. Hospitalizations and emergency department visits due to opioid poisoning in Canada. Ottawa: Canadian Institute for Health Information; 2016.
-
- Bruneau J, Roy E, Arruda N, et al. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012;107:1318–27. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical